Synapse - Steven Horwitz

Results (664)

Complete remission with devimistat (CPI-613) in refractory Burkitt lymphoma

Meeting Abstract

Nikolaenko, L.; Pardee, T.; Steiner, R.; Abramson, J. S.; Horwitz, S. M.; Matasar, M. J.; Owens, C.; Rodriguez-Rivera, I.; Straus, D. J.; Luther, S.; more...
Blood (2021)

Fulltext@MSK | Save

End of treatment peripheral blood TCR evaluation for minimal residual disease evaluation in peripheral T-cell lymphomas

Meeting Abstract

Mehta-Shah, N.; Jacobsen, E. D.; Fehniger, T. A.; Kahl, B. S.; Bartlett, N. L.; Cashen, A. F.; Ghobadi, A.; Reagan, B.; Fischer, A.; Moskowitz, A. J.; more...
Blood (2021)

Fulltext@MSK | Save

Frontline brentuximab vedotin plus cyclophosphamide, doxorubicin and prednisone in patients with peripheral T-cell lymphoma with less than 10% CD30 expression (SGN35-032, trial in progress)

Meeting Abstract

Jagadeesh, D.; Knowles, S.; Horwitz, S. M.
Blood (2021)

Fulltext@MSK | Save

TP53 mutations identify high-risk peripheral T-cell lymphoma patients treated with CHOP-based chemotherapy

Meeting Abstract

Johnson, W. T.; Ganesan, N.; Epstein-Peterson, Z. D.; Maccaro, C.; Galasso, N.; Sauter, C. S.; Neuman, R.; Khan, N.; Moskowitz, A. J.; Dogan, A.; more...
Blood (2021)

Fulltext@MSK | Save

The ECHELON-2 Trial: 5-year exploratory subgroup analyses of a randomized, double-blind, phase 3 study of brentuximab vedotin and CHP (A + CHP) vs CHOP in frontline treatment of pts with CD30-positive peripheral T-cell lymphoma

Meeting Abstract

Horwitz, S. M.; Savage, K. J.; Illidge, T.; Plyer, S. P.; Advani, R.; Shustov, A. R.; Bartlett, N. L.; Pro, B.; Jacobsen, E. D.; Koch, R.; more...
Blood (2021)

Fulltext@MSK | Save

Phase 2a study of the dual SYK/JAK inhibitor cerdulatinib (ALXN2075) as monotherapy in patients with relapsed/refractory peripheral T-cell lymphoma

Meeting Abstract

Horwitz, S. M.; Feldman, T. A.; Ye, J. C.; Khodadoust, M. S.; Munoz, J.; Hamlin, P. A.; Kim, Y. H.; Wilcox, R. A.; Patel, M. R.; Coffey, G. P.; more...
Blood (2021)

Fulltext@MSK | Save

Updates from ongoing, first-in-human phase 1 dose escalation and expansion study of TTI-621, a novel biologic targeting CD47, in patients with relapsed or refractory hematologic malignancies

Meeting Abstract

Horwitz, S. M.; James, M. F.; Maris, M.; Lue, J. K.; Sawas, A.; Okada, C.; Feldman, T. A.; Sokol, L.; Mei, M.; Flinn, I. W.; more...
Blood (2021)

Fulltext@MSK | Save

T-cell lymphomas: Online education significantly improves clinicians' knowledge of therapeutic advances

Meeting Abstract

Heller, E. J.; Williams, S. L.; Smith, K. P.; Horwitz, S. M.
Blood (2021)

Fulltext@MSK | Save

A global phase 2 study of valemetostat tosylate (valemetostat) in patients with relapsed or refractory (R/R) peripheral T-cell lymphoma (PTCL), including R/R adult T-cell leukemia/lymphoma (ATL) - VALENTINE-PTCL01

Meeting Abstract

Foss, F. M.; Porcu, P.; Horwitz, S. M.; Izutsu, K.; Ishitsuka, K.; Kato, K.; Jin, J.; Du, Y.; Inoue, A.
Blood (2021)

Fulltext@MSK | Save

Clinical outcomes and CNS relapse risk in patients with primary cutaneous DLBCL, leg type treated in the rituximab era: Long-term follow-up of a single-center experience

Meeting Abstract

Falchi, L.; Qiu, A.; Ewalt, M. D.; Batlevi, C. L.; Caron, P. C.; Hamlin, P. A.; Hamilton, A.; Horwitz, S. M.; Joffe, E.; Khan, N.; more...
Blood (2021)

Fulltext@MSK | Save

Steven M Horwitz

Results (664)

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract